Request for Notification From Industry Organizations Interested in Participating in the Selection Process for Nonvoting Industry Representatives on Public Advisory Committees and Panels and Request for Nonvoting Industry Representatives on Public Advisory Committees and Panels, 66382-66384 [2010-27230]
Download as PDF
<![CDATA[
emcdonald on DSK2BSOYB1PROD with NOTICES
66382
Federal Register / Vol. 75, No. 208 / Thursday, October 28, 2010 / Notices
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
8732310001. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the Agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: The Pediatric Advisory
Committee (PAC) will meet to discuss
donor and banked human milk. FDA is
convening the meeting to obtain and
discuss information and data that will
provide the Agency with a better
understanding of current practices, and
potential benefits and risks associated
with the donation and banking of
human milk.
FDA recognizes the benefits
associated with breastfeeding, and is
focusing this meeting on issues related
to banking human milk. Human milk is
banked for use by infants in need of
donated milk. The agenda for the
meeting will include presentations and
discussions on the benefits and risks of
human milk banking practices as they
relate to pre-term and term infant
populations. Topics will include, but
not be limited to, infectious disease
risks, State regulations and current
practices in donor and human milk
banking.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/default.
htm. Scroll down to the appropriate
advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 29, 2010.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interesting in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
VerDate Mar<15>2010
16:13 Oct 27, 2010
Jkt 223001
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before
November 18, 2010. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by November 19, 2010.
Comments: FDA is opening a docket
to allow for additional public comments
to be submitted to the Agency on the
issues before the Pediatric Advisory
Committee beginning October 28, 2010,
and closing January 6, 2011. All
comments received on or before
November 29, 2010, will be provided to
the committee members. All comments
received after November 29, 2010, will
be taken into consideration by the
Agency. Interested persons are
encouraged to use the docket to submit
either electronic or written comments
regarding this meeting (see ADDRESSES).
Submit electronic comments to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management, Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. It is only
necessary to send one set of comments.
It is no longer necessary to send two
copies of mailed comments. Identify
comments with the docket number
found in brackets in the heading of this
document. Received comments may be
seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Walter
Ellenberg, at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: October 25, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–27283 Filed 10–27–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Request for Notification From Industry
Organizations Interested in
Participating in the Selection Process
for Nonvoting Industry
Representatives on Public Advisory
Committees and Panels and Request
for Nonvoting Industry
Representatives on Public Advisory
Committees and Panels
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is requesting that
any industry organization interested in
participating in the selection of
nonvoting industry representatives to
serve on the National Mammography
Quality Assurance Advisory Committee
(NMQAAC) and certain device panels of
the Medical Devices Advisory
Committee (MDAC) in the Center for
Devices and Radiological Health (CDRH)
notify FDA in writing. A nominee may
either be self nominated or nominated
by an organization to serve as a
nonvoting industry representative.
Nominations will be accepted for
current vacancies effective with this
notice.
SUMMARY:
Any industry organizations
interested in participating in the
selection of an appropriate nonvoting
member to represent industry interests
must send a letter stating that interest to
the FDA by November 29, 2010, for the
vacancies listed in this document.
Concurrently, nomination materials for
prospective candidates should be sent to
FDA by November 29, 2010.
ADDRESSES: Send all letters of interest
and nominations to Margaret J. Ames
(see FOR FURTHER INFORMATION CONTACT).
FOR FURTHER INFORMATION CONTACT:
Margaret J. Ames, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 5234, Silver Spring,
DATES:
E:\FR\FM\28OCN1.SGM
28OCN1
Federal Register / Vol. 75, No. 208 / Thursday, October 28, 2010 / Notices
MD 20993, 301–796–5960, e-mail:
margaret.ames@fda.hhs.gov.
The
agency intends to add nonvoting
industry representatives to the following
advisory committees:
SUPPLEMENTARY INFORMATION:
I. CDRH—Various Committees and
Panels
A. National Mammography Quality
Assurance Advisory Committee
(NMQAAC)
The Mammography Quality Standards
Reauthorization Act of 2004 (Pub. L.
108–365) requires the addition of at
least two industry representatives with
expertise in mammography equipment
to the NMQAAC.
developments concerning breast
imaging which should be considered in
the oversight of mammography
facilities; (7) determining whether there
exists a shortage of mammography
facilities in rural and health
professional shortage areas and
determining the effects of personnel on
access to the services of such facilities
in such areas; (8) determining whether
there will exist a sufficient number of
medical physicists after October 1, 1999;
and (9) determining the costs and
benefits of compliance with these
requirements.
B. Certain Panels of the Medical Devices
Advisory Committee
The medical device panels perform
the following functions: (1) Review and
B. Medical Devices Advisory Committee evaluate data on the safety and
(MDAC)
effectiveness of marketed and
investigational devices and make
Section 520(f)(3) of the Federal Food,
recommendations for their regulation;
Drug, and Cosmetic Act (FD&C Act) (21
(2) advise the Commissioner of Food
U.S.C. 360j(f)(3)), as amended by the
and Drugs (the Commissioner) regarding
Medical Device Amendments of 1976,
provides that each medical device panel recommended classification or
reclassification of these devices into one
include one nonvoting member to
of three regulatory categories; (3) advise
represent the interests of the medical
on any possible risks to health
device manufacturing industry.
associated with the use of devices; (4)
II. CDRH—Committee and Panels
advise on formulation of product
Functions
development protocols; (5) review
FDA is requesting nominations for
premarket approval applications for
medical devices; (6) review guidelines
nonvoting members representing
industry interests for vacancies listed in and guidance documents; (7)
recommend exemption to certain
table 1 of this document as follows:
devices from the application of portions
TABLE 1—NOMINATIONS REQUESTED of the FD&C Act; (8) advise on the
FOR NONVOTING MEMBERS REP- necessity to ban a device; (9) respond to
RESENTING INDUSTRY INTERESTS ON requests from the agency to review and
PUBLIC ADVISORY COMMITTEES AND make recommendations on specific
issues or problems concerning the safety
PANELS
and effectiveness of devices; and (10)
make recommendations on the quality
Committee name or
Approximate date
in the design of clinical studies
panel
needed
regarding the safety and effectiveness of
NMQAAC ...................... February 1, 2011.
marketed and investigational devices.
Anesthesiology and
Respiratory Therapy
Devices Panel.
General and Plastic
Surgery Devices
Panel.
December 1, 2011.
September 1, 2011.
emcdonald on DSK2BSOYB1PROD with NOTICES
A. NMQAAC
The functions of the NMQAAC are to
advise FDA on: (1) Developing
appropriate quality standards and
regulations for mammography facilities;
(2) developing appropriate standards
and regulations for bodies accrediting
mammography facilities under this
program; (3) developing regulations
with respect to sanctions; (4) developing
procedures for monitoring compliance
with standards; (5) establishing a
mechanism to investigate consumer
complaints; (6) reporting new
VerDate Mar<15>2010
16:13 Oct 27, 2010
Jkt 223001
III. Selection Procedure
Any industry organization interested
in participating in the selection of an
appropriate nonvoting member to
represent industry interests should send
a letter stating that interest to the
contact person (see FOR FURTHER
INFORMATION CONTACT) within 30 days of
publication of this notice. Within the
subsequent 30 days, FDA will send a
letter to each organization that has
expressed an interest, attaching a
complete list of all such organizations,
and a list of all nominees along with
´
´
their current resumes. The letter will
also state that it is the responsibility of
the interested organizations to confer
with one another and to select a
candidate, within 60 days after the
receipt of the FDA letter, to serve as the
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
66383
nonvoting member to represent industry
interests for a particular committee or
device panel. The interested
organizations are not bound by the list
of nominees in selecting a candidate.
However, if no individual is selected
within the 60 days, the Commissioner of
Food and Drugs will select the
nonvoting member to represent industry
interests.
IV. Qualifications
A. NMQAAC
Persons nominated for membership as
an industry representative on the
NMQAAC must meet the following
criteria: (1) Demonstrate expertise in
mammography equipment; and (2) be
able to discuss equipment specifications
and quality control procedures affecting
mammography equipment. The industry
representative must be able to represent
the industry perspective on issues and
actions before the advisory committee,
serve as liaison between the committee
and interested industry parties, and
facilitate dialogue with the advisory
committee on mammography equipment
issues.
B. MDAC
Persons nominated for the device
panels should be full-time employees of
firms that manufacture products that
would come before the panel, or
consulting firms that represent
manufacturers, or have similar
appropriate ties to industry.
V. Application Procedure
Individuals may self nominate and/or
an organization may nominate one or
more individuals to serve as a nonvoting
industry representative. Within 30 days,
the following information should be
sent to the FDA contact person (see FOR
FURTHER INFORMATION CONTACT): A
current curriculum vitae of each
nominee, current business and/or home
address, telephone number, e-mail
address, and the name of the committee
or device panel of interest. FDA will
forward all nominations to the
organizations expressing interest in
participating in the selection process for
the committee or panel. (Persons who
nominate themselves as nonvoting
industry representatives will not
participate in the selection process).
FDA has a special interest in ensuring
that women, minority groups,
individuals with physical disabilities,
and small businesses are adequately
represented on its advisory committees,
and therefore, encourages nominations
for appropriately qualified candidates
from these groups.
This notice is issued under the
Federal Advisory Committee Act (5
E:\FR\FM\28OCN1.SGM
28OCN1
66384
Federal Register / Vol. 75, No. 208 / Thursday, October 28, 2010 / Notices
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: October 22, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–27230 Filed 10–27–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5383–N–23]
Notice of Proposed Information
Collection for Public Comment;
Exigent Health and Safety Deficiency
Correction Certification
Office of the Assistant
Secretary for Public and Indian
Housing, HUD.
ACTION: Notice.
AGENCY:
The proposed information
collection requirement described below
will be submitted to the Office of
Management and Budget (OMB) for
review, as required by the Paperwork
Reduction Act. The Department is
soliciting public comments on the
subject proposal.
DATES: Comments Due Date: December
27, 2010.
ADDRESSES: Interested persons are
invited to submit comments regarding
this proposal. Comments should refer to
the proposal by name/or OMB Control
number and should be sent to: Colette
Pollard, Department Reports
Management Officer, Office of the Chief
Information Officer, Department of
Housing and Urban Development, 451
7th Street, SW., Room 4160,
Washington, DC 20410–5000; telephone
202.402.3400, (this is not a toll-free
number) or email Colette_Pollard@
hud.gov. Persons with hearing or speech
impairments may access this number
through TTY by calling the toll-free
Federal Information Relay Service at
(800) 877–8339. (Other than the HUD
USER information line and TTY
numbers, telephone numbers are not
toll-free.), or e-mail Ms.
Colette_Pollard@hud.gov. Persons with
hearing or speech impairments may
access this number through TTY by
calling the toll-free Federal Information
Relay Service at (800) 877–8339. (Other
than the HUD USER information line
and TTY numbers, telephone numbers
are not toll-free.)
FOR FURTHER INFORMATION CONTACT:
Arlette Mussington, Office of Policy,
Programs and Legislative Initiatives,
PIH, Department of Housing and Urban
emcdonald on DSK2BSOYB1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:13 Oct 27, 2010
Jkt 223001
Development, 451 Seventh Street, SW.,
(L’Enfant Plaza, Room 2206),
Washington, DC 20410; telephone: 202–
402–4109, (this is not a toll-free
number) for copies of the proposed
forms and other available documents.
SUPPLEMENTARY INFORMATION: The
Department will submit the proposed
information collection to OMB for
review, as required by the Paperwork
Reduction Act of 1995 (44 U.S.C.
Chapter 35, as amended). This Notice is
soliciting comments from members of
the public and affected agencies
concerning the proposed collection of
information to: (1) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (2) evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information; (3) enhance the quality,
utility, and clarity of the information to
be collected; and (4) minimize the
burden of the collection of information
on those who are to respond, including
through the use of appropriate
automated collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
This Notice also lists the following
information:
Title of Proposal: Exigent Health and
Safety Deficiency Correction
Certification.
OMB Control Number: 2577–0241.
Description of the need for the
information and proposed use: HUD’s
Uniform Physical Condition Standards
(UPCS) regulation (24 CFR part 5,
subpart G) provides that HUD housing
must be decent, safe, sanitary, and in
good repair. Public housing agencies
(PHAs) must maintain housing in a
manner that meets prescribed physical
condition standards to be considered
decent, safe, sanitary, and in good
repair. The UPCS regulation also
provides that all area and components
of the housing must be free of health
and safety hazards. HUD conducts
physical inspections of the HUD-funded
housing to determine if the UPCS
standards are being met. Pursuant to the
UPCS inspection protocol, at the end of
the inspection (or at the end of each day
of a multi-day inspection) the inspector
provides the property representative
with a copy of the ‘‘Notification of
Exigent and Fire Safety Hazards
Observed’’ form. Each exigent health
and safety (EHS) deficiency that the
inspector observed that day is listed on
the form. The property representative
signs the form acknowledging receipt.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
PHAs are to correct EHS deficiencies
(i.e., emergency work orders) within 24
hours. PHAs are to notify HUD, using
the electronic format, within three
business days of the date of inspection,
which is the date the PHA was provided
notice of these deficiencies, that the
deficiencies were corrected within the
prescribed time frames.
Agency form number: None.
Members of affected public: Public
Housing Agencies.
Estimation of the total number of
hours needed to prepare the information
collection including number of
respondents: 1,236 respondents
annually with one response per
respondent. Average time per response
is .44 hours and the total burden hours
are 333.57.
Status of the proposed information
collection: Extension of currently
approved collection.
Authority: Section 3506 of the Paperwork
Reduction Act of 1995, 44 U.S.C. Chapter 35,
as amended.
Dated: October 21, 2010.
Merrie Nichols-Dixon,
Acting Deputy Assistant Secretary, Office of
Policy, Program and Legislative Initiatives.
[FR Doc. 2010–27310 Filed 10–27–10; 8:45 am]
BILLING CODE 4210–67–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5415–N–14]
Notice of Availability: Notice of
Funding Availability (NOFA) for HUD’s
Fiscal Year 2010 Housing Choice
Voucher Family Self-Sufficiency
Program
Office of the Chief of the
Human Capital Officer, HUD.
ACTION: Notice.
AGENCY:
HUD announces the
availability on its Web site of the
applicant information, submission
deadlines, funding criteria, and other
requirements for HUD’s Fiscal Year (FY)
2010 Housing Choice Voucher Family
Self-Sufficiency (HCV FSS) Program.
The HCV FSS NOFA makes available
approximately $60 million under the
Consolidated Appropriations Act 2010.
The purpose of the HCV FSS program is
to promote the development of local
strategies to coordinate the use of
assistance under the HCV program with
public and private resources to enable
participating families to increase earned
income and financial literacy, reduce or
eliminate the need for welfare
assistance, and make progress toward
economic independence and selfsufficiency.
SUMMARY:
E:\FR\FM\28OCN1.SGM
28OCN1
]]>Agencies
[Federal Register Volume 75, Number 208 (Thursday, October 28, 2010)]
[Notices]
[Pages 66382-66384]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-27230]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Request for Notification From Industry Organizations Interested
in Participating in the Selection Process for Nonvoting Industry
Representatives on Public Advisory Committees and Panels and Request
for Nonvoting Industry Representatives on Public Advisory Committees
and Panels
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting that any
industry organization interested in participating in the selection of
nonvoting industry representatives to serve on the National Mammography
Quality Assurance Advisory Committee (NMQAAC) and certain device panels
of the Medical Devices Advisory Committee (MDAC) in the Center for
Devices and Radiological Health (CDRH) notify FDA in writing. A nominee
may either be self nominated or nominated by an organization to serve
as a nonvoting industry representative. Nominations will be accepted
for current vacancies effective with this notice.
DATES: Any industry organizations interested in participating in the
selection of an appropriate nonvoting member to represent industry
interests must send a letter stating that interest to the FDA by
November 29, 2010, for the vacancies listed in this document.
Concurrently, nomination materials for prospective candidates should be
sent to FDA by November 29, 2010.
ADDRESSES: Send all letters of interest and nominations to Margaret J.
Ames (see FOR FURTHER INFORMATION CONTACT).
FOR FURTHER INFORMATION CONTACT: Margaret J. Ames, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, rm. 5234, Silver Spring,
[[Page 66383]]
MD 20993, 301-796-5960, e-mail: margaret.ames@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: The agency intends to add nonvoting industry
representatives to the following advisory committees:
I. CDRH--Various Committees and Panels
A. National Mammography Quality Assurance Advisory Committee (NMQAAC)
The Mammography Quality Standards Reauthorization Act of 2004 (Pub.
L. 108-365) requires the addition of at least two industry
representatives with expertise in mammography equipment to the NMQAAC.
B. Medical Devices Advisory Committee (MDAC)
Section 520(f)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C
Act) (21 U.S.C. 360j(f)(3)), as amended by the Medical Device
Amendments of 1976, provides that each medical device panel include one
nonvoting member to represent the interests of the medical device
manufacturing industry.
II. CDRH--Committee and Panels Functions
FDA is requesting nominations for nonvoting members representing
industry interests for vacancies listed in table 1 of this document as
follows:
TABLE 1--Nominations Requested for Nonvoting Members Representing
Industry Interests on Public Advisory Committees and Panels
------------------------------------------------------------------------
Committee name or panel Approximate date needed
------------------------------------------------------------------------
NMQAAC............................... February 1, 2011.
Anesthesiology and Respiratory December 1, 2011.
Therapy Devices Panel.
General and Plastic Surgery Devices September 1, 2011.
Panel.
------------------------------------------------------------------------
A. NMQAAC
The functions of the NMQAAC are to advise FDA on: (1) Developing
appropriate quality standards and regulations for mammography
facilities; (2) developing appropriate standards and regulations for
bodies accrediting mammography facilities under this program; (3)
developing regulations with respect to sanctions; (4) developing
procedures for monitoring compliance with standards; (5) establishing a
mechanism to investigate consumer complaints; (6) reporting new
developments concerning breast imaging which should be considered in
the oversight of mammography facilities; (7) determining whether there
exists a shortage of mammography facilities in rural and health
professional shortage areas and determining the effects of personnel on
access to the services of such facilities in such areas; (8)
determining whether there will exist a sufficient number of medical
physicists after October 1, 1999; and (9) determining the costs and
benefits of compliance with these requirements.
B. Certain Panels of the Medical Devices Advisory Committee
The medical device panels perform the following functions: (1)
Review and evaluate data on the safety and effectiveness of marketed
and investigational devices and make recommendations for their
regulation; (2) advise the Commissioner of Food and Drugs (the
Commissioner) regarding recommended classification or reclassification
of these devices into one of three regulatory categories; (3) advise on
any possible risks to health associated with the use of devices; (4)
advise on formulation of product development protocols; (5) review
premarket approval applications for medical devices; (6) review
guidelines and guidance documents; (7) recommend exemption to certain
devices from the application of portions of the FD&C Act; (8) advise on
the necessity to ban a device; (9) respond to requests from the agency
to review and make recommendations on specific issues or problems
concerning the safety and effectiveness of devices; and (10) make
recommendations on the quality in the design of clinical studies
regarding the safety and effectiveness of marketed and investigational
devices.
III. Selection Procedure
Any industry organization interested in participating in the
selection of an appropriate nonvoting member to represent industry
interests should send a letter stating that interest to the contact
person (see FOR FURTHER INFORMATION CONTACT) within 30 days of
publication of this notice. Within the subsequent 30 days, FDA will
send a letter to each organization that has expressed an interest,
attaching a complete list of all such organizations, and a list of all
nominees along with their current r[eacute]sum[eacute]s. The letter
will also state that it is the responsibility of the interested
organizations to confer with one another and to select a candidate,
within 60 days after the receipt of the FDA letter, to serve as the
nonvoting member to represent industry interests for a particular
committee or device panel. The interested organizations are not bound
by the list of nominees in selecting a candidate. However, if no
individual is selected within the 60 days, the Commissioner of Food and
Drugs will select the nonvoting member to represent industry interests.
IV. Qualifications
A. NMQAAC
Persons nominated for membership as an industry representative on
the NMQAAC must meet the following criteria: (1) Demonstrate expertise
in mammography equipment; and (2) be able to discuss equipment
specifications and quality control procedures affecting mammography
equipment. The industry representative must be able to represent the
industry perspective on issues and actions before the advisory
committee, serve as liaison between the committee and interested
industry parties, and facilitate dialogue with the advisory committee
on mammography equipment issues.
B. MDAC
Persons nominated for the device panels should be full-time
employees of firms that manufacture products that would come before the
panel, or consulting firms that represent manufacturers, or have
similar appropriate ties to industry.
V. Application Procedure
Individuals may self nominate and/or an organization may nominate
one or more individuals to serve as a nonvoting industry
representative. Within 30 days, the following information should be
sent to the FDA contact person (see FOR FURTHER INFORMATION CONTACT): A
current curriculum vitae of each nominee, current business and/or home
address, telephone number, e-mail address, and the name of the
committee or device panel of interest. FDA will forward all nominations
to the organizations expressing interest in participating in the
selection process for the committee or panel. (Persons who nominate
themselves as nonvoting industry representatives will not participate
in the selection process).
FDA has a special interest in ensuring that women, minority groups,
individuals with physical disabilities, and small businesses are
adequately represented on its advisory committees, and therefore,
encourages nominations for appropriately qualified candidates from
these groups.
This notice is issued under the Federal Advisory Committee Act (5
[[Page 66384]]
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: October 22, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-27230 Filed 10-27-10; 8:45 am]
BILLING CODE 4160-01-P
